AGC Biologics has made a change in executive leadership, appointed by their board of directors. Robert Broeze will retire on March 5, 2019 after a career spanning over 35 years in the biopharmaceutical industry. Mark Womack, previously the senior vice president of integration management and business excellence for AGC Biologics, will succeed Bob as the chief business officer, effective immediately.
 
Bob joined CMC Biologics (now AGC Biologics) in 2015 as senior vice president of global business development, bringing more than 30 years of industry experience to the role. “Bob played a key role in shaping and directing our successful business development program and has been an exceptional leader, passionate about our mission and committed to our principles and values,” said Gustavo Mahler, chief executive officer, AGC Biologics. “Bob’s leadership has been instrumental in realizing our vision and achieving significant growth of our business. We wish him well in his retirement and appreciate his support as we transition leadership.”
 
Mark has served on AGC Biologics’ executive team in the role of senior vice president of integration management and business excellence since the beginning of 2018. Mark has over 25 years of experience leading large-scale business integrations and transformations of Fortune 200 client companies both as the chief operating officer of several international management consultancies, as well as with his own management and leadership consultancy corporation.
 
“Mark’s knowledge and leadership abilities will enable AGC Biologics to further grow its business development capabilities and infrastructure. I look forward to continuing to work with Mark in his new role,” said Mr. Mahler.